Bioyond Robotics (奔曜科技)

A Shanghai company led by former ABB Robotics executives that sells standardized, modular benchtop lab robots in China and abroad.

1. Core Product / Service

Shanghai Benyao Technology Co., Ltd. (上海奔曜科技有限公司), founded 2021-03-26, sells a catalogue of standard products rather than custom integration projects:

• LabGenius hardware. G3, G5 and G7 benchtop pipetting robots, from single-arm modular units up to dual-arm, ultra-high-throughput open-deck platforms. S-series compact plate movers with force-controlled grippers and vision. M-series mobile robots that move materials between labs.
• LabMate configurations. Ready-made combinations of G- and S-series units: Gleam, Polar, Horizon, and Beacon (a vertical unit with a consumable stacker).
• Software and other products. LabMind, lab software with a device-driver library for third-party instruments, and the BIOYOND AutoSeq genetic-analysis system.
• Custom projects. Larger installations for drug screening, synthetic biology, cell and gene therapy, omics and clinical diagnostics.
• ODM. The website offers ODM partnering. No partners are named.

The public website gives no numeric specifications and no prices. In 2025 the company began building a manufacturing base of about RMB 100M in Nanjing Jiangbei New Area, with planned capacity of about 1,000 robots a year.

2. Target Users & Pain Points

• Who buys. Pharma and biotech R&D, CROs, synthetic-biology and omics labs, clinical diagnostics, materials and agriculture labs, universities and government institutes.
• Pain solved. Skilled lab technicians are scarce and getting more expensive, and manual pipetting is error-prone. Bioyond sells "zero-threshold" automation that runs unattended 24/7 and that a bench scientist can set up without an automation engineer.
• Customer claims. The company said it served "100+ well-known life-science companies" in April 2023 and "1,000+ customers" in October 2024. Both figures are self-reported. No customers are named publicly.

3. Competitive Landscape

4. Unique Observations

• The most product-like company in China's lab-automation cohort. Bioyond has a tiered SKU ladder (G3 → G5 → G7), sells pre-configured bundles, and goes to market through a third-party distributor (DKSH, Australia, August 2026) and ODM. This looks like an industrial-robot company's playbook rather than a systems integrator's, and it fits the founders' ABB background.
• The customer count needs care. It rose tenfold in 18 months (100+ to 1,000+) with no named customers. That jump more likely reflects a change in what is counted (individual labs or distributor end-users) than tenfold growth on a like-for-like basis.
• There is little evidence for the "AI" claim. Press materials now describe "AI-driven autonomous laboratory solutions," but no closed-loop AI experiment case has been published. The product evidence points to good automation hardware with scheduling software.
• Funding has gone quiet while capacity expands. No round has been disclosed since October 2024, yet the company is building a 1,000-units-a-year plant. Local Nanjing reports credit the move to a Boyuan-managed regional fund's network, which suggests local or project-level money rather than a new equity round. This is not confirmed.
• Liquid handling is the most crowded segment. Benchtop pipetting faces a dozen Chinese competitors plus Opentrons. Over time Bioyond will compete on distribution, service and cost unless LabMind becomes a real software moat.
• Possible naming conflict abroad. "LabGenius" is also the name of a London AI antibody company, which may cause trademark or search confusion overseas.

5. Financials / Funding

• Revenue, orders and margins: not disclosed. A December 2025 local-government report describes orders as "surging." No figures were given.
• Funding rounds:

• Total raised: about RMB 300M across the first four rounds (company figure, April 2023). Adding the A3 round, the total is likely RMB 500M or more. Aggregator figures of US$29–37M appear to leave out the A3 round.
• Valuation: not disclosed.
• Registered capital: RMB 4.27M or RMB 4.81M depending on the source. Neither has been confirmed against the official registry.

6. People & Relationships

• Founder and CEO: 汤阳 (Tang Yang). He joined ABB Robotics in 2004 and later headed ABB Robotics' China R&D center and its consumer-goods and service-robotics business unit. He is the legal representative and controlling shareholder; his stake was about 28% as of October 2024 per one source. No other co-founders or a CTO are named publicly.
• Investors: HongShan Seed, Qiming and Boyuan have each invested in at least three rounds. Lilly Asia Ventures, CICC Capital, Panlin Capital and Zhangke Herun have also invested.
• Footprint: Headquartered in Zhangjiang / Pudong, Shanghai. Other entities and sites: a Zhuhai subsidiary and a Nanjing Jiangbei manufacturing base. The company says it has teams in Europe and the US.
• Channel partners: DKSH, distributor for Australia since August 2026. Bioyond is scheduled to exhibit at analytica China (November 2026) and SLAS 2027 (San Diego).
• Peers: megarobo, xuanren-tech, xtalpi, shuye-tech.